In re Nektar Therapeutics: Ninth Circuit Affirms Dismissal of Securities Class Action Arising from Failure of Clinical Drug Trial   | Cooley LLP

Summary - On May 19, 2022, a panel of the Ninth Circuit unanimously affirmed the district court’s dismissal of a putative securities fraud class action accusing Nektar...

Related Keywords

,Atossa Genetics Inc ,Bofi Holding Inc ,Nektar Therapeutics ,Securities Exchange ,First Solar Inc ,Ninth Circuit ,Plainview Report ,Securities Exchange Act ,Materially False ,Misleading Statements ,Loss Causation ,Atossa Genetics ,Mineworker Pension Scheme ,Solar Inc ,Bofi Holding ,